Azithromycin to Improve Latency in Exam Indicated Cerclage Control Trial

Preterm Birth Clinical Trial

— ALEC  

Official title:

Azithromycin to Improve Latency in Exam Indicated Cerclage: a Randomized Control Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05132829
• Other study ID #: 21D.746
• Status: Recruiting
• Phase: Phase 4
• Start date: December 20, 2021
• Est. completion date: June 2025

Study information

• Verified date: June 2023
• Source: Thomas Jefferson University
• Contact: Rupsa Boelig, MD
• Phone: 2159555000
• Email: Rupsa.boelig[@]jefferson.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Azithromycin is an antibiotic that is effective against bacteria that been associated with preterm birth (PTB). The purpose of this study is to evaluate if the addition of azithromycin prior to exam indicated cerclage prolongs gestation. A cerclage is a suture placed in the cervix to prolong gestation.

Description:

Preterm birth (PTB) continues to be a leading cause of neonatal morbidity and mortality. The rate of spontaneous PTB (delivery before 37 weeks gestation) is one in ten pregnancies and a history of prior preterm birth remains a risk factor for recurrence. The pathophysiology of cervical insufficiency leading to PTB remains poorly understood.

While interventions for PTB prevention are limited, the American College of Obstetrics and Gynecology (ACOG) supports the use of cervical cerclage. A physical exam indicated cerclage may be placed in the setting of painless cervical dilation in the second trimester. The cerclage is believed to provide mechanical support to a weakened cervix and promote the cervical mucosal plug as a barrier to ascending infection.

While many aspects of cerclage use have been extensively studied, the use of antibiotics prior to placement remains under evaluated. While antibiotic use is recommended during cesarean section, preterm premature rupture of membranes (PPROM), and obstetric anal sphincter injuries (OASIS), ACOG currently does not recommend perioperative antibiotics or prophylactic tocolytics at the time of cerclage placement citing insufficient evidence.

Miller et al. performed a randomized controlled trial (RCT) showing an increased incidence of pregnancy prolongation by at least 28 days among women who received indomethacin and perioperative antibiotics in the setting of an exam indicated cerclage compared to those who received no perioperative medications (92.3% vs 62.5%, p=0.01). Participants in the experimental arm received cefazolin or clindamycin if they had a penicillin allergy. Cefazolin is a first generation cephalosporin that has activity against gram positive cocci and gram negative rods and is commonly used for surgical prophylaxis. Clindamycin is a protein synthesis inhibitor and covers gram positive organisms and anaerobic bacteria, making it an appropriate alternative in cases of penicillin allergy. The use of cefazolin specifically with indomethacin has been studied retrospectively and showed a significant improvement in gestational latency (adjusted relative risk [aRR] 1.21, 95% CI 1.05-1.40) and birth weight (+489.8 grams, 95% CI 64.6-915.0).

The use of prolonged azithromycin with cerclage has been studied in a prospective, non- randomized fashion. In this study, patients were given 500mg azithromycin for 3 days and this was repeated every 10 days until 34 weeks. Patients who received this regimen and a cerclage had lower PTB (65.7% vs 5.7%, p<0.001) and reduced immediate fetal mortality (37.1% vs 0%, p<0.001).

The aim of our study is to determine if the addition of azithromycin prior to exam indicated cerclage prolongs gestation. Azithromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome and inhibits transpeptidation. It is effective against a wide variety of bacteria, specifically mycoplasma which has been associated with preterm birth. Azithromycin is currently used in obstetrics for patients undergoing nonelective cesarean delivery and as part of latency antibiotics in the setting of PPROM.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: June 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Pregnant women with singleton pregnancies

• =18 years old

• Estimated gestational age less than 24 weeks

• Meet criteria for an exam indicated cerclage

• Patients must also be able to provide consent, demonstrate an understanding of the purpose of the study, and agree to the study protocol.

Exclusion Criteria:

• Human immunodeficiency virus (HIV) positive status

• Known prolonged QT syndrome

• Major fetal congenital anomalies

• Temperature of 100.4 F or higher

• Prior cerclage during the current pregnancy

• Contraindication to indomethacin

• Allergy to both penicillin and clindamycin

• Received indomethacin or any antibiotics within 7 days before their presentation

Related Conditions & MeSH terms

• Anti-Bacterial Agents
• Azithromycin
• Cefazolin
• Obstetric Labor Complications
• Obstetric Labor, Premature
• Physiological Effects of Drugs
• Pregnancy Complications
• Premature Birth
• Preterm Birth
• Uterine Cervical Incompetence

Intervention

Drug:
• Azithromycin 1 gram IV
Perioperative addition of azithromycin at the time of physical exam indicated cerclage placement.
• Cefazolin and indomethacin
Perioperative standard of care with cefazolin and indomethacin

Locations

Country	Name	City	State
United States	Northwestern University	Chicago	Illinois
United States	Rutgers Robert Wood Johnson	New Brunswick	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
Thomas Jefferson University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Gestational Latency Achieved Between Cerclage Placement and Time of Delivery	Mean gestational latency achieved Between Cerclage Placement and Time of Delivery	24 weeks following cerclage placement
Secondary	Preterm birth <37 weeks, <34 weeks, <32 weeks, <28 weeks, <24 weeks	Preterm delivery stratified by gestational age at delivery in weeks	at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.
Secondary	Mean gestational age at delivery	Measured in weeks	at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.
Secondary	chorioamnionitis	Histologic or clinical diagnosis	at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.
Secondary	birth weight	measured in grams	at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.
Secondary	Admission to neonatal intensive care unit	If admitted, measured in days	at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.
Secondary	Neonatal Morbidity and Mortality	including apgars, Respiratory Distress Syndrome, Bronchopulmonary dysplasia, Retinopathy of prematurity, Intraventricular hemorrhage (IVH) (grade 3 or 4), patent ductus arteriosus, and neonatal death	within 28 days of delivery
Secondary	Cervicovaginal cytokine analysis	Measurement of proinflammatory cytokines in pg/ml (IL-1B, IL-2, IL-4, IL-6, IL-8, IL-8, IL-10, G-CSF, GM-CSF, MCP-1, TNF-a, IFN-g, CCL5, VEGF, ICAM-1) from cervicovaginal fluid at the time of cerclage placement and at follow up 1-4 weeks after placement	Cerclage placement and 1-4 weeks after